康希诺(06185.HK)逆涨一成越50天线 新冠疫苗据报已获墨西哥订单及或获印尼采购
康希诺生物-B(06185.HK)研发新冠肺炎疫苗或获印尼采用及据报已获墨西哥采购订单。该股继昨天整固後,今早逆市重越50天线(186.5元),最高见195元,现造193.8元,逆弹9.9%,成交增至144万股,涉资2.738亿元。
据内媒报道指,康希诺生物与中国工程院院士陈薇团队合作研发新冠肺炎疫苗国际III期临床试验於墨西哥取得进展,且墨西哥已签订框架协议向康希诺采购3,500万剂新冠疫苗,此外,道琼斯报道,印尼一位高级卫生官员透露,印尼正在采取措施批准中国新冠肺炎候选疫苗投入紧急使用。阿联酋上月已批准一款中国新冠疫苗投入紧急使用。印尼政府表示,到今年底将向中国的科兴控股生物技术、中国医药集团及康希诺生物采购1,800万剂新冠疫苗,这些公司新冠疫苗仍在全球多个地点进行临床试验。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.